Global Gastritis Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Gastritis Market Size

• The global Gastritis market size was valued at USD 189.75 Million in 2025and is expected to reach USD 259.68 Million by 2033, at a CAGR of 4.00% during the forecast period
• The market growth is largely fueled by the increasing prevalence of gastrointestinal disorders, changing dietary habits, and rising incidence of Helicobacter pylori infections, leading to growing demand for effective diagnosis and treatment solutions across healthcare settings
• Furthermore, rising awareness regarding digestive health, increasing adoption of advanced gastrointestinal therapies, and growing demand for effective acid suppression and stomach lining protection treatments are establishing gastritis solutions as essential components of modern gastrointestinal care. These converging factors are accelerating the uptake of Gastritis solutions, thereby significantly boosting the industry's growth

Gastritis Market Analysis

• Gastritis solutions, including proton pump inhibitors, antacids, H2 antagonists, antibiotics, and advanced gastrointestinal diagnostic technologies, are becoming increasingly important in modern healthcare settings due to the rising prevalence of stomach inflammation disorders and growing need for effective digestive health management
• The escalating demand for gastritis solutions is primarily fueled by increasing incidence of Helicobacter pylori infections, unhealthy dietary habits, rising stress levels, and growing awareness regarding gastrointestinal health and early disease diagnosis
• North America dominated the gastritis market with the largest revenue share of 37.6% in 2025, characterized by advanced healthcare infrastructure, high awareness regarding gastrointestinal disorders, and strong presence of leading pharmaceutical companies, with the U.S. experiencing substantial growth in the adoption of advanced gastritis treatment therapies and diagnostic procedures driven by increasing healthcare expenditure and growing prevalence of digestive disorders
• Asia-Pacific is expected to be the fastest growing region in the gastritis market during the forecast period due to rising healthcare expenditure, increasing prevalence of gastrointestinal diseases, expanding access to healthcare services, and growing awareness regarding digestive health management across emerging economies
• The oral segment accounted for the largest market revenue share of 67.4% in 2025, driven by the extensive use of oral tablets, capsules, and liquid formulations in gastritis treatment

Report Scope and Gastritis Market Segmentation

Gastritis Market Trends

“Increasing Adoption of Targeted Therapies and Advanced Diagnostic Approaches”

• A significant and accelerating trend in the global Gastritis market is the growing adoption of targeted therapeutic approaches and advanced diagnostic technologies aimed at improving disease management and patient outcomes
• For instance, healthcare providers are increasingly utilizing non-invasive diagnostic methods such as breath tests, stool antigen tests, and advanced endoscopic imaging technologies for the early detection and accurate diagnosis of gastritis and associated gastrointestinal disorders
• The increasing focus on Helicobacter pylori eradication therapies and personalized treatment strategies is also transforming gastritis management practices. Pharmaceutical companies are developing improved antibiotic combinations, proton pump inhibitors, and mucosal protective agents to enhance treatment effectiveness and reduce recurrence rates
• Furthermore, rising awareness regarding the impact of dietary habits, alcohol consumption, stress, and long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) on gastric health is encouraging preventive care and early medical intervention among patients
• The growing integration of digital healthcare platforms and telemedicine services is also improving patient access to gastroenterology consultations, follow-up care, and treatment monitoring, particularly in remote and underserved areas
• This trend toward earlier diagnosis, personalized therapy, and patient-centered gastrointestinal care is reshaping treatment approaches and supporting continued innovation in the Gastritis market globally

Gastritis Market Dynamics

Driver

“Rising Prevalence of Gastrointestinal Disorders and Increasing Lifestyle-Related Risk Factors”

• The increasing prevalence of gastrointestinal disorders and the growing exposure to lifestyle-related risk factors are major factors driving the growth of the Gastritis market
• For instance, unhealthy dietary patterns, excessive alcohol consumption, smoking, chronic stress, and prolonged use of NSAIDs are contributing significantly to the rising incidence of gastritis across both developed and emerging economies
• The growing burden of Helicobacter pylori infections worldwide is also increasing demand for effective diagnostic tools and treatment solutions for acute and chronic gastritis management
• Furthermore, increasing healthcare awareness and improved access to gastroenterology services are encouraging more patients to seek early diagnosis and treatment for gastric disorders, supporting market expansion
• The expanding geriatric population, which is more susceptible to chronic gastrointestinal conditions and medication-related gastric complications, is also contributing to rising demand for gastritis therapeutics
• In addition, ongoing pharmaceutical research activities focused on developing advanced acid suppression therapies, anti-inflammatory agents, and gastroprotective drugs are further strengthening market growth opportunities globally

Restraint/Challenge

“Antibiotic Resistance and Side Effects Associated with Long-Term Therapies”

• The increasing prevalence of antibiotic resistance among Helicobacter pylori strains remains a significant challenge for the Gastritis market, potentially reducing the effectiveness of conventional eradication therapies
• For instance, resistance to commonly prescribed antibiotics such as clarithromycin and metronidazole has created treatment complexities in several regions, requiring alternative therapeutic strategies and combination regimens
• In addition, prolonged use of proton pump inhibitors and certain gastric medications may be associated with side effects such as nutrient deficiencies, gastrointestinal imbalances, and increased risk of recurrent infections, raising concerns regarding long-term treatment safety
• The lack of awareness regarding early symptoms of gastritis and delayed diagnosis in low-resource settings may also contribute to disease progression and complications such as peptic ulcers or gastric bleeding
• Furthermore, limited healthcare access and high diagnostic procedure costs in some developing regions may restrict timely treatment adoption among affected patient populations
• Addressing these challenges through improved antimicrobial stewardship, development of novel treatment regimens, enhanced patient education, and expanded access to gastrointestinal healthcare services will be essential for sustaining long-term growth in the global Gastritis market

Gastritis Market Scope

The market is segmented on the basis of treatment, type, route of administration, end-users, and distribution channel.

• By Treatment

On the basis of treatment, the Gastritis market is segmented into acid blocking medications, acid reducing medications, antacids, antibiotics, and others. The acid reducing medications segment dominated the largest market revenue share of 41.8% in 2025, driven by the widespread use of proton pump inhibitors (PPIs) and H2 receptor blockers in gastritis management. These medications are highly preferred due to their effectiveness in reducing stomach acid production and promoting healing of the gastric lining. Physicians commonly prescribe acid reducing therapies for both acute and chronic gastritis patients because of their proven clinical efficacy and long-term symptom relief. The increasing prevalence of gastrointestinal disorders associated with unhealthy dietary habits, alcohol consumption, and stress has significantly contributed to segment growth. In addition, rising awareness regarding early diagnosis and treatment of acid-related digestive conditions is supporting market demand. Pharmaceutical companies continue to develop advanced formulations with improved patient compliance and reduced side effects. Expanding healthcare access and increasing availability of over-the-counter gastric medications are further strengthening segment dominance. Furthermore, growing investments in gastroenterology care and rising patient preference for non-invasive treatment approaches are expected to sustain strong market growth during the forecast period.

The antibiotics segment is anticipated to witness the fastest CAGR of 22.5% from 2026 to 2033, driven by the increasing prevalence of Helicobacter pylori infections, which are a major cause of gastritis globally. Antibiotics are increasingly prescribed in combination therapies to eradicate bacterial infections and prevent recurrence of gastric inflammation. Healthcare providers are focusing on targeted antimicrobial treatment strategies to improve patient outcomes and reduce complications such as peptic ulcers. Rising awareness regarding infection-related gastritis and expanding diagnostic testing for H. pylori are significantly supporting segment growth. In addition, advancements in combination antibiotic therapies and growing antimicrobial research are accelerating treatment effectiveness. Increasing healthcare expenditure and expanding gastroenterology treatment services globally are expected to further strengthen future market expansion.

• By Type

On the basis of type, the Gastritis market is segmented into acute gastritis, chronic gastritis, erosive gastritis, and non-erosive gastritis. The chronic gastritis segment held the largest market revenue share of 44.6% in 2025, driven by the increasing prevalence of long-term gastric inflammation associated with bacterial infections, autoimmune conditions, and prolonged NSAID usage. Chronic gastritis is widely diagnosed among aging populations and individuals with unhealthy dietary and lifestyle habits. Healthcare providers increasingly focus on long-term disease management and prevention of complications such as gastric ulcers and stomach cancer. The rising burden of gastrointestinal disorders and increasing adoption of diagnostic endoscopy procedures have significantly contributed to segment growth. In addition, growing awareness regarding digestive health and preventive medical checkups is supporting earlier diagnosis and treatment initiation. Pharmaceutical advancements in acid suppression therapies and mucosal protective agents are further strengthening treatment outcomes. The increasing availability of specialized gastroenterology services and expanding healthcare infrastructure globally continue to support market demand. Furthermore, rising healthcare spending and supportive reimbursement systems are expected to maintain segment dominance throughout the forecast period.

The erosive gastritis segment is expected to witness the fastest CAGR of 20.9% from 2026 to 2033, driven by the growing incidence of severe gastric mucosal damage linked to alcohol abuse, stress-related conditions, and prolonged medication use. Erosive gastritis cases often require intensive medical attention due to risks associated with gastrointestinal bleeding and ulcer formation. Healthcare providers are increasingly utilizing advanced diagnostic imaging and endoscopy techniques to identify erosive gastric conditions at earlier stages. Rising awareness regarding gastrointestinal complications and increasing hospitalization rates for severe digestive disorders are significantly contributing to segment expansion. In addition, advancements in gastroprotective medications and emergency gastric care management are supporting improved clinical outcomes. Expanding access to specialized gastrointestinal treatment centers is expected to further accelerate future market growth.

• By Route of Administration

On the basis of route of administration, the Gastritis market is segmented into oral and parenteral. The oral segment accounted for the largest market revenue share of 67.4% in 2025, driven by the extensive use of oral tablets, capsules, and liquid formulations in gastritis treatment. Oral administration is widely preferred due to its convenience, ease of use, and high patient compliance in both acute and chronic gastritis management. Physicians commonly prescribe oral acid suppressants, antacids, and antibiotics because they provide effective symptom relief and are suitable for long-term treatment. The increasing prevalence of digestive disorders and growing awareness regarding self-medication for mild gastric symptoms have significantly contributed to segment growth. In addition, expanding availability of over-the-counter gastrointestinal medications is supporting broader market penetration. Pharmaceutical companies continue to introduce advanced oral drug formulations with improved absorption and reduced side effects. Rising healthcare accessibility and growing adoption of outpatient treatment approaches are further strengthening segment dominance. Furthermore, increasing online pharmacy availability and consumer preference for home-based treatment are expected to sustain strong future growth.

The parenteral segment is projected to witness the fastest CAGR of 19.6% from 2026 to 2033, driven by increasing utilization of injectable therapies in severe gastritis cases requiring hospitalization and rapid symptom control. Parenteral administration is particularly important for patients experiencing acute gastric bleeding, severe nausea, or inability to tolerate oral medications. Healthcare providers increasingly utilize intravenous proton pump inhibitors and supportive therapies in emergency and critical care settings. The growing incidence of erosive gastritis and gastrointestinal complications is significantly contributing to segment growth. In addition, advancements in injectable gastrointestinal medications and hospital care infrastructure are improving treatment outcomes. Rising investments in emergency gastroenterology services and critical care facilities are expected to further support future market expansion globally.

• By End-Users

On the basis of end-users, the Gastritis market is segmented into hospitals, homecare, specialty clinics, and others. The hospitals segment dominated the largest market revenue share of 53.7% in 2025, driven by the high volume of gastritis-related admissions, endoscopic procedures, and gastrointestinal treatments performed in hospital settings. Hospitals serve as primary treatment centers for severe gastritis cases due to the availability of advanced diagnostic technologies, gastroenterologists, and emergency care services. Increasing prevalence of gastrointestinal disorders and rising incidences of stress-related gastric complications have significantly boosted hospital-based treatment demand. In addition, hospitals increasingly invest in specialized gastroenterology departments and advanced endoscopy systems to improve patient care. Growing healthcare expenditure and expansion of multispecialty hospitals globally are further supporting segment growth. Rising awareness regarding digestive health and early disease diagnosis is also contributing to higher patient visits to hospitals. Furthermore, advancements in integrated healthcare management systems and supportive reimbursement policies are expected to sustain strong segment dominance during the forecast period.

The homecare segment is anticipated to witness the fastest CAGR of 21.8% from 2026 to 2033, driven by the increasing preference for home-based treatment and self-management of chronic digestive conditions. Patients with mild to moderate gastritis increasingly prefer homecare solutions due to convenience, reduced treatment costs, and easier medication adherence. The growing availability of over-the-counter gastric medications and telemedicine consultation services is significantly supporting segment growth. In addition, rising awareness regarding preventive digestive healthcare and dietary management is accelerating homecare adoption. Healthcare providers are increasingly integrating digital monitoring and remote consultation services for chronic gastrointestinal patients. Expanding e-commerce pharmaceutical services and growing patient preference for personalized healthcare solutions are expected to further strengthen future market expansion.

• By Distribution Channel

On the basis of distribution channel, the Gastritis market is segmented into hospital pharmacy, retail pharmacy, online pharmacies, and others. The retail pharmacy segment held the largest market revenue share of 46.5% in 2025, driven by the widespread availability of gastritis medications and increasing consumer preference for convenient medication access. Retail pharmacies play a crucial role in distributing over-the-counter antacids, acid suppressants, and prescription gastrointestinal therapies. Patients frequently prefer retail pharmacies due to accessibility, pharmacist consultation services, and immediate product availability. The increasing prevalence of digestive disorders and rising awareness regarding self-treatment of mild gastric symptoms have significantly contributed to segment growth. In addition, expanding pharmacy chains and growing healthcare accessibility in urban and rural regions are supporting broader market penetration. Pharmaceutical companies continue to strengthen retail distribution networks to improve product reach and customer engagement. Rising consumer spending on digestive health products and supportive healthcare infrastructure are expected to sustain segment dominance during the forecast period.

The online pharmacies segment is expected to witness the fastest CAGR of 24.3% from 2026 to 2033, driven by the rapid expansion of digital healthcare platforms and increasing consumer preference for home delivery medication services. Online pharmacies provide easy access to gastrointestinal medications, competitive pricing, and convenient purchasing experiences. The growing adoption of telemedicine and digital prescription services is significantly accelerating segment growth. Consumers increasingly prefer online pharmaceutical platforms because of improved accessibility, especially in remote and underserved regions. In addition, rising smartphone penetration, internet usage, and digital payment adoption are supporting broader e-pharmacy expansion globally. Pharmaceutical companies and healthcare providers are actively investing in digital healthcare ecosystems and secure online prescription verification systems. Regulatory advancements supporting e-pharmacy operations are expected to further contribute to robust future market growth.

Gastritis Market Regional Analysis

• North America dominated the gastritis market with the largest revenue share of 37.6% in 2025, characterized by advanced healthcare infrastructure, high awareness regarding gastrointestinal disorders, and strong presence of leading pharmaceutical companies
• The region benefits from increasing adoption of advanced gastritis treatment therapies, growing utilization of diagnostic procedures such as endoscopy, and rising healthcare expenditure
• Furthermore, increasing prevalence of digestive disorders, strong research activities in gastrointestinal therapeutics, and growing awareness regarding early diagnosis and treatment are significantly contributing to market growth across North America

U.S. Gastritis Market Insight

The U.S. gastritis market captured the largest revenue share within North America in 2025, driven by increasing prevalence of digestive disorders and rising adoption of advanced treatment and diagnostic solutions. The country is witnessing substantial growth in the use of proton pump inhibitors, antacids, and other gastritis therapies due to growing patient awareness and increasing healthcare accessibility. In addition, rising healthcare investments, strong pharmaceutical innovation, and increasing demand for effective gastrointestinal disease management are supporting market expansion in the U.S.

Europe Gastritis Market Insight

Europe gastritis market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by increasing prevalence of gastrointestinal disorders and growing awareness regarding digestive health management. The region’s advanced healthcare systems, combined with increasing demand for effective treatment solutions and early diagnostic procedures, are fostering market growth. Moreover, rising healthcare expenditure, growing elderly population, and advancements in gastrointestinal therapeutics are contributing significantly to the expansion of the gastritis market in Europe.

U.K. Gastritis Market Insight

The United Kingdom gastritis market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by increasing awareness regarding digestive health and rising adoption of advanced gastrointestinal treatment solutions. The country’s well-established healthcare infrastructure and growing demand for effective acid suppression therapies and diagnostic procedures are supporting market growth. Furthermore, increasing government healthcare initiatives and growing patient focus on preventive healthcare are expected to further stimulate the gastritis market in the U.K.

Germany Gastritis Market Insight

The Germany gastritis market is expected to expand at a considerable CAGR during the forecast period, fueled by strong pharmaceutical manufacturing capabilities, advanced healthcare infrastructure, and increasing awareness regarding gastrointestinal disease management. Germany’s emphasis on healthcare innovation and early diagnosis is promoting the adoption of advanced gastritis treatment therapies and diagnostic technologies. In addition, rising prevalence of digestive disorders and increasing investments in healthcare modernization are positively influencing market growth in the country.

Asia-Pacific Gastritis Market Insight

Asia-Pacific gastritis market is expected to be the fastest growing region in the Gastritis market during the forecast period due to rising healthcare expenditure, increasing prevalence of gastrointestinal diseases, expanding access to healthcare services, and growing awareness regarding digestive health management across emerging economies. Rapid improvements in healthcare infrastructure, increasing government healthcare initiatives, and rising accessibility to gastrointestinal treatment services are further accelerating market growth. In addition, the region’s large patient population and increasing awareness regarding lifestyle-related digestive disorders are contributing significantly to the adoption of gastritis treatment solutions.

Japan Gastritis Market Insight

The Japan gastritis market is gaining momentum due to the country’s advanced healthcare infrastructure, increasing aging population, and growing awareness regarding gastrointestinal disorders. Rising adoption of advanced diagnostic technologies and effective acid suppression therapies is supporting market growth. Furthermore, Japan’s focus on preventive healthcare and early diagnosis of digestive diseases is contributing to increasing utilization of gastritis treatment solutions across healthcare settings.

China Gastritis Market Insight

The China gastritis market accounted for the largest market revenue share in Asia-Pacific in 2025, attributed to expanding healthcare infrastructure, increasing prevalence of gastrointestinal disorders, and rising healthcare expenditure. The country is witnessing growing demand for advanced digestive disease treatment solutions supported by improving healthcare accessibility and increasing awareness regarding gastrointestinal health management. In addition, strong pharmaceutical manufacturing capabilities, government healthcare modernization initiatives, and expanding hospital networks are key factors propelling market growth in China.

Gastritis Market Share

The Gastritis industry is primarily led by well-established companies, including:

• Pfizer Inc. (U.S.)
• AstraZeneca plc (U.K.)
• Takeda Pharmaceutical Company Limited (Japan)
• GlaxoSmithKline plc (U.K.)
• Sanofi S.A. (France)
• Bayer AG (Germany)
• Abbott Laboratories (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• Novartis AG (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sun Pharmaceutical Industries Ltd. (India)
• Reddy’s Laboratories Ltd. (India)
• Cipla Limited (India)
• Lupin Limited (India)
• Aurobindo Pharma Limited (India)
• Alkem Laboratories Ltd. (India)
• Glenmark Pharmaceuticals Ltd. (India)
• Hoffmann-La Roche Ltd. (Switzerland)
• Merck & Co., Inc. (U.S.)
• Eisai Co., Ltd. (Japan)

Latest Developments in Global Gastritis Market

• In May 2021, Phathom Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved VOQUEZNA Triple Pak and VOQUEZNA Dual Pak for the treatment of Helicobacter pylori infection in adults. The therapies utilize vonoprazan, a novel potassium-competitive acid blocker (P-CAB), combined with antibiotics to improve eradication rates and address growing antibiotic resistance associated with gastritis and peptic ulcer disease treatment
• In April 2021, Phathom Pharmaceuticals announced positive topline results from its pivotal Phase III PHALCON-HP trial evaluating vonoprazan-based therapy for H. pylori infection. The study met all primary and secondary endpoints and demonstrated superior eradication rates compared to conventional proton pump inhibitor-based therapies, highlighting a major advancement in gastritis-associated infection treatment
• In October 2023, Phathom Pharmaceuticals received FDA approval for reformulated vonoprazan tablets for VOQUEZNA Triple Pak and VOQUEZNA Dual Pak used in H. pylori treatment. The reformulated therapy was developed to ensure long-term product stability while continuing to deliver potent acid suppression and improved bacterial eradication in gastritis patients
• In November 2023, Phathom Pharmaceuticals announced FDA approval of VOQUEZNA® (vonoprazan) tablets for the treatment of erosive gastroesophageal reflux disease (GERD) and associated heartburn in adults. The approval marked the first major innovation in acid-suppression therapy in the U.S. market in over 30 years and strengthened the adoption of P-CAB therapies in gastritis and acid-related gastrointestinal disorders
• In February 2024, researchers published a comprehensive clinical review titled “Vonoprazan: A Review in Helicobacter pylori Infection,” highlighting the increasing adoption of vonoprazan-based therapies for gastritis and peptic ulcer disease management. The review emphasized improved acid suppression, enhanced patient compliance, and higher eradication success rates compared to traditional proton pump inhibitor regimens

SKU-54485